Insight Molecular Diagnostics (IMDX) Operating Margin (2020 - 2025)
Insight Molecular Diagnostics' Operating Margin history spans 6 years, with the latest figure at 4249.23% for Q3 2025.
- For Q3 2025, Operating Margin rose 750294.0% year-over-year to 4249.23%; the TTM value through Sep 2025 reached 1392.91%, up 475561.0%, while the annual FY2024 figure was 3245.14%, 157275.0% down from the prior year.
- Operating Margin for Q3 2025 was 4249.23% at Insight Molecular Diagnostics, down from 1900.0% in the prior quarter.
- Across five years, Operating Margin topped out at 1969.7% in Q1 2023 and bottomed at 11752.17% in Q3 2024.
- The 5-year median for Operating Margin is 1518.18% (2023), against an average of 2209.38%.
- The largest annual shift saw Operating Margin surged 5168307bps in 2021 before it plummeted -1023399bps in 2024.
- A 5-year view of Operating Margin shows it stood at 783.14% in 2021, then dropped by -4bps to 748.59% in 2022, then plummeted by -788bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
- Per Business Quant, the three most recent readings for IMDX's Operating Margin are 4249.23% (Q3 2025), 1900.0% (Q2 2025), and 318.01% (Q1 2025).